Screener
Biogen BIIB Amortization and impairment of acquired intangible assets
Amortization and impairment of acquired intangible assets at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets.
The source filing: Biogen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 6:36 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000875045-26-000075
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 529.6 | 399.0 | 1,068.6 | 833.1 |
| Acquired in-process research and development, upfront and milestone expense | 164.0 | 46.6 | 198.0 | 247.3 |
| Selling, general and administrative | 709.7 | 583.8 | 1,317.0 | 1,156.3 |
| Amortization and impairment of acquired intangible assets | 168.2 | 130.9 | 304.7 | 242.7 |
| Collaboration profit sharing/(loss reimbursement) | 68.8 | 75.0 | 143.0 | 133.1 |
| (Gain) loss on fair value remeasurement of contingent consideration | 2.5 | 13.2 | 23.0 | 22.8 |
| Restructuring charges | 165.4 | (0.7) | 173.3 | 34.6 |
| Other (income) expense, net | 18.5 | 48.7 | 38.2 | 117.1 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Biogen's amortization and impairment of acquired intangible assets?
- Biogen (BIIB) reported amortization and impairment of acquired intangible assets of $168.2M in Q2 2026.
- How has Biogen's amortization and impairment of acquired intangible assets changed year-over-year?
- Biogen's amortization and impairment of acquired intangible assets increased by 28.5% year-over-year, from $130.9M to $168.2M.
- What is the long-term trend for Biogen's amortization and impairment of acquired intangible assets?
- Over 3 years (2022 to 2025), Biogen's amortization and impairment of acquired intangible assets has grown at a 12.1% compound annual growth rate (CAGR), from $365.9M to $515M.
- What does amortization and impairment of acquired intangible assets mean?
- The non-cash expense related to the systematic write-down of the value of acquired intangible assets, such as patents or licenses, over their useful lives. It also includes impairment charges if the asset's value declines significantly.
Ask your AI about Biogen's amortization and impairment of acquired intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude